Schroder Investment Management Group Sells 3,642 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Schroder Investment Management Group lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 17,311 shares of the medical equipment provider’s stock after selling 3,642 shares during the period. Schroder Investment Management Group’s holdings in Zimmer Biomet were worth $1,825,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ZBH. Geode Capital Management LLC grew its stake in shares of Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after purchasing an additional 125,852 shares during the period. Van ECK Associates Corp grew its position in Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after acquiring an additional 218,688 shares during the period. Norges Bank acquired a new position in Zimmer Biomet during the fourth quarter worth $216,223,000. Equity Investment Corp lifted its holdings in shares of Zimmer Biomet by 57.2% during the fourth quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock valued at $107,855,000 after acquiring an additional 371,653 shares during the period. Finally, Sound Shore Management Inc. CT acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $81,447,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Raymond James cut their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Truist Financial reiterated a “hold” rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. JMP Securities restated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $124.15.

Insider Activity

In related news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Stock Down 4.6 %

Shares of Zimmer Biomet stock opened at $107.46 on Monday. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $129.50. The business has a fifty day simple moving average of $107.32 and a 200 day simple moving average of $107.23. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock has a market cap of $21.39 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm posted $2.20 earnings per share. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. Zimmer Biomet’s dividend payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.